For the 29 million people battling diabetes across the U.S., the financial burden of treating the disease is already high – and rising.
After a 10News investigation in February dug into the varying costs of prescription medications, several people reached out asking us to look into the cost of diabetes. We did – and found several families struggling to make ends meet among the 600,000 diabetic Tennesseans. (read more)
San Diego-based ViaCyte said it is ready to move into human testing with a new product intended for patients with Type 1 diabetes who are at high risk for acute, life-threatening complications from severe episodes of low blood sugar (hypoglycemia).
ViaCyte said Monday that healthcare regulators in both the United States and Canada have permitted the company to proceed with the early stage clinical trial, which calls for enrolling roughly 40 patients at medical centers that include UC San Diego and the University of Alberta in Edmonton, Canada. The goal of the trial is to assess the safety of the PEC-Direct product candidate and provide definitive evidence of efficacy. (read more)
The most successful treatment for type 2 diabetes may work by changing the makeup of gut bacteria.
Metformin is commonly prescribed to help people with type 2 diabetes control their blood sugar. It is also being tested as an anti-ageing treatment.
The drug is generally believed to work by reducing the amount of glucose made in the liver, which would in turn lower blood sugar levels. But some observations suggest this isn’t the whole story. (read more)